期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Endocrine therapy of short duration prevents local and contralateral recurrence of ductal carcinoma in situ of the breast:A multicenter retrospective cohort study in China
1
作者 Zhen Wang Zining Jin +19 位作者 Huanrui Zhang Guiying Xu Dianlong Zhang fengqi fang Hua Xing Jia Wang Baoliang Guo Guolian Zhu Yongzhi Liu Jieqing Li Zhengang Cai Liang Sun Yuting Zhang Tianyang Zhou Chang Liu Baosen Zhou Feng Jin Yan Zhang Dong Song Bo Chen 《Chinese Medical Journal》 SCIE CAS CSCD 2024年第14期1756-1758,共3页
To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone r... To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone receptor-positive DCIS.Selective estrogen receptor modulators(such as the commonly used tamoxifen and toremifene)and aromatase inhibitors(AIs)are the currently used AET drugs.However,long-term AET is accompanied by severe side effects such as menopausal symptoms,endometrial carcinoma,cardiovascular events,venous thromboembolic events,osteoporosis,and joint pain that can significantly reduce patients’quality of life.It was reported that only 50%of the patients completed the recommended 5-year AET mainly because of side effects,while higher adherence rates were observed with shorter-duration regimens.[1,2]Therefore,de-escalation of AET should be considered to reduce the side effects of AET and improve adherence. 展开更多
关键词 REGIMEN BREAST DRUGS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部